Patents by Inventor Meibi Dai

Meibi Dai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline form of fluvatinib or fluvatinib methanesulfonate and preparation method therefor
    Patent number: 12643861
    Abstract: Disclosed in the present invention is a crystalline form of fluvatinib or fluvatinib methanesulfonate, and a preparation method therefor. The crystalline form I of the fluvatinib has characteristic diffraction peaks as shown in FIG. 1. The crystalline form of the fluvatinib methanesulfonate may take multiple forms, including seven crystalline forms, forms I-VII, wherein crystalline form III has characteristic diffraction peaks as shown in FIG. 9. Said crystalline forms are suited to manufacturing processes for fluvatinib methanesulfonate formulations.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: June 2, 2026
    Assignees: CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD, YAOPHARMA CO., LTD.
    Inventors: Shuai He, Yang Zhang, Qiang Liu, Zhengxia Chen, Meibi Dai, Bin Fan, Peiyu Xie
  • Fluorovinylbenzamide compound as PD-L1 immunomodulator
    Patent number: 12509440
    Abstract: The present invention relates to a PD-L1 immunomodulator, and specifically discloses a compound of formula (I) as a PD-L1 immunomodulator, a pharmaceutically acceptable salt or an isomer thereof.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: December 30, 2025
    Assignee: NovaOnco JS Therapeutics Co., Ltd.
    Inventors: Yang Zhang, Yuanfeng Xia, Deheng Sun, Jian Zuo, Zhengxia Chen, Meibi Dai, Jian Li, Shuhui Chen
  • FLUOROQUINOXALINONE DERIVATIVE FOR SELECTIVELY INHIBITING PARP1
    Publication number: 20250295642
    Abstract: Disclosed is a series of fluorine-substituted heterocyclic compounds, and specifically, disclosed are a compound represented by formula (XII) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 6, 2023
    Publication date: September 25, 2025
    Inventors: Zhengxia CHEN, Meibi DAI, Yang ZHANG, Shuhui CHEN
  • Pyridine derivative as FGFR and VEGFR dual inhibitors
    Patent number: 12378241
    Abstract: FGFR and VEGFR dual inhibitors, specifically being a compound represented by formula (I) or a pharmaceutically acceptable salt.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: August 5, 2025
    Assignee: CGeneTech (Suzhou,China) CO., Ltd.
    Inventors: Zhengxia Chen, Meibi Dai, Yang Zhang, Shuhui Chen
  • Azaindole derivative and use thereof as FGFR and C-Met inhibitor
    Patent number: 12312347
    Abstract: A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: May 27, 2025
    Assignee: WUXI LIFE FOUNTAIN BIOTECH CO., LTD
    Inventors: Yang Zhang, Zhengxia Chen, Yikai Wang, Meibi Dai, Jie Li, Zhen Gong, Jian Li, Shuhui Chen
  • Pyrazolopyridine compound as RET inhibitor and application thereof
    Patent number: 12297197
    Abstract: Disclosed is a series of pyrazolopyridine compounds, and application thereof in the preparation of RET kinase inhibitors for treatment. Specifically disclosed is the compound represented by formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: May 13, 2025
    Assignee: GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY
    Inventors: Jiansong Wang, Zhengxia Chen, Zhibo Luo, Meibi Dai, Yang Zhang, Shuhui Chen, Yingxia Bao, Wei Wang, Zhoufan Xie
  • CRYSTAL FORM OF METHYLPYRAZOLE-SUBSTITUTED PYRIDOIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREFOR
    Publication number: 20240409534
    Abstract: A crystal form of a methylpyrazole-substituted pyridoimidazole compound (II) and a preparation method therefor.
    Type: Application
    Filed: January 26, 2022
    Publication date: December 12, 2024
    Inventors: Zhengxia Chen, Meibi Dai, Yang Zhang, Shuhui Chen
  • Vinylpyridine carboxamide compound as PD-L1 immunomodulator
    Patent number: 12152013
    Abstract: Disclosed is a PD-L1 inhibitor, and specifically disclosed is a compound of formula (I) as a PD-L1 immunomodulator, a pharmaceutically acceptable salt or an isomer thereof.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: November 26, 2024
    Assignee: NovaOnco JS Therapeutics Co., Ltd.
    Inventors: Yang Zhang, Yuanfeng Xia, Zhengxia Chen, Meibi Dai, Deheng Sun, Jian Zuo, Jian Li, Shuhui Chen
  • Crystal form of azaindole derivative and use thereof
    Patent number: 11919898
    Abstract: A crystal form of an azaindole derivative and a preparation method thereof are disclosed.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: March 5, 2024
    Assignee: SHENZHEN LINGFANG BIOTECH CO., LTD.
    Inventors: Zhengxia Chen, Meibi Dai, Yang Zhang
  • CRYSTAL FORM OF AZAINDOLE DERIVATIVE AND USE THEREOF
    Publication number: 20230322760
    Abstract: A crystal form of an azaindole derivative and a preparation method thereof are disclosed.
    Type: Application
    Filed: January 15, 2021
    Publication date: October 12, 2023
    Applicant: Wuxi Life Fountain Biotech Co., Ltd
    Inventors: ZHENGXIA CHEN, MEIBI DAI, YANG ZHANG
  • CRYSTALLINE FORM OF FLUVATINIB OR FLUVATINIB METHANESULFONATE AND PREPARATION METHOD THEREFOR
    Publication number: 20230106064
    Abstract: Disclosed in the present invention is a crystalline form of fluvatinib or fluvatinib methanesulfonate, and a preparation method therefor. The crystalline form I of the fluvatinib has characteristic diffraction peaks as shown in FIG. 1. The crystalline form of the fluvatinib methanesulfonate may take multiple forms, including seven crystalline forms, forms I-VII, wherein crystalline form III has characteristic diffraction peaks as shown in FIG. 9. Said crystalline forms are suited to manufacturing processes for fluvatinib methanesulfonate formulations.
    Type: Application
    Filed: March 16, 2021
    Publication date: April 6, 2023
    Applicants: CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD, YAOPHARMA CO., LTD.
    Inventors: Shuai HE, Yang ZHANG, Qiang LIU, Zhengxia CHEN, Meibi DAI, Bin FAN, Peiyu XIE
  • Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof
    Patent number: 11440903
    Abstract: The present invention provides a salt form, a crystal form, and a preparation method of a compound as an FGFR4 inhibitor and medical uses thereof.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: September 13, 2022
    Assignees: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD, GUANGDONG XIANQIANG PHARMACEUTICAL CO., LTD
    Inventors: Chaofeng Long, Yang Zhang, Zhengxia Chen, Xiaoxin Chen, Zhuowei Liu, Meibi Dai, Zhiqiang Liu, Shuhui Chen
  • PYRIDINE DERIVATIVE AS FGFR AND VEGFR DUAL INHIBITORS
    Publication number: 20220267324
    Abstract: FGFR and VEGFR dual inhibitors, specifically being a compound represented by formula (I) or a pharmaceutically acceptable salt.
    Type: Application
    Filed: July 24, 2020
    Publication date: August 25, 2022
    Inventors: Zhengxia CHEN, Meibi DAI, Yang ZHANG, Shuhui CHEN
  • PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF
    Publication number: 20220220104
    Abstract: Disclosed is a series of pyrazolopyridine compounds, and application thereof in the preparation of RET kinase inhibitors for treatment. Specifically disclosed is the compound represented by formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 3, 2020
    Publication date: July 14, 2022
    Applicants: GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY, MEDSHINE DISCOVERY INC.
    Inventors: Jiansong WANG, Zhengxia CHEN, Zhibo LUO, Meibi DAI, Yang ZHANG, Shuhui CHEN, Yingxia BAO, Wei WANG, Zhoufan XIE
  • VINYLPYRIDINE CARBOXAMIDE COMPOUND AS PD-L1 IMMUNOMODULATOR
    Publication number: 20220144806
    Abstract: Disclosed is a PD-L1 inhibitor, and specifically disclosed is a compound of formula (I) as a PD-L1 immunomodulator, a pharmaceutically acceptable salt or an isomer thereof.
    Type: Application
    Filed: February 3, 2020
    Publication date: May 12, 2022
    Applicant: ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.,
    Inventors: Yang Zhang, Yuanfeng Xia, Zhengxia Chen, Meibi Dai, Deheng Sun, Jian Zuo, Jian Li, Shuhui Chen
  • FLUOROVINYLBENZAMIDE COMPOUND AS PD-L1 IMMUNOMODULATOR
    Publication number: 20220119368
    Abstract: The present invention relates to a PD-L1 immunomodulator, and specifically discloses a compound of formula (I) as a PD-L1 immunomodulator, a pharmaceutically acceptable salt or an isomer thereof.
    Type: Application
    Filed: February 3, 2020
    Publication date: April 21, 2022
    Applicant: ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.,Ltd
    Inventors: Yang Zhang, Yuanfeng Xia, Deheng Sun, Jian Zuo, Zhengxia Chen, Meibi Dai, Jian Li, Shuhui Chen
  • Quinoline derivative and use thereof as tyrosine kinase inhibitor
    Patent number: 11161817
    Abstract: A quinoline derivative compound shown in formula (II), a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to a tyrosine kinase inhibitor.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: November 2, 2021
    Assignees: CHONGQING PHARMACEUTICAL INDUSTRIAL RESEARCH INSTITUTE CO. LTD., YAOPHARMA CO., LTD.
    Inventors: Yang Zhang, Zhengxia Chen, Meibi Dai, Wenju Li, Jian Li, Shuhui Chen
  • AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR
    Publication number: 20210253571
    Abstract: A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 19, 2019
    Publication date: August 19, 2021
    Inventors: Yang ZHANG, Zhengxia CHEN, Yikai WANG, Meibi DAI, Jie LI, Zhen GONG, Jian LI, Shuhui CHEN
  • Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor
    Patent number: 11078194
    Abstract: Disclosed in the present invention are a salt form and a crystal form serving as FGFR and VEGFR inhibitor compounds, a preparation method therefor, and medical uses thereof.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: August 3, 2021
    Assignee: HARBIN ZHENBAO PHARMACEUTICAL CO., LTD.
    Inventors: Zhengxia Chen, Yang Zhang, Meibi Dai, Hongfei Cheng, Suqin Yang, Wenju Li, Jian Li, Shuhui Chen
  • FGFR4 inhibitor and preparation method and use thereof
    Patent number: 11008292
    Abstract: Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: May 18, 2021
    Inventors: Zhengxia Chen, Chaofeng Long, Yang Zhang, Xiaoxin Chen, Yikai Wang, Meibi Dai, Zhuowei Liu, Haixia Zhao, Xing Liu, Guoping Hu, Jian Li, Shuhui Chen